# Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

> **NCT04255875** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 52 (actual)

## Conditions studied

- Healthy
- Sickle Cell Anemia

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** PF-07209326
- **BIOLOGICAL:** PF-07209326

## Key facts

- **NCT ID:** NCT04255875
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-05
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04255875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04255875, "Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04255875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*